Answers are grounded in this paper and cite their sources.
The prognosis of advanced/metastatic GISTs has improved significantly through treatment with a combination of neoadjuvant and/or adjuvant imatinib, a tyrosine kinase inhibitor, and surgical resection. However, GISTs often show variable response to neoadjuvant therapy and there are currently no well-established guidelines for some of the management decisions faced by both medical and surgical oncologists. We present two cases of patients with advanced duodenal gastrointestinal stromal tumors who developed tumor-bowel fistulas while on neoadjuvant tyrosine kinase inhibitor therapy. Both patients experienced tumor progression while on neoadjuvant therapy as well as treatment-related complications, including the formation of a fistula connecting the tumor and bowel lumen. This phenomenon has seldom been mentioned in the existing literature, and has rarely been discussed as a life-threatening complication of tyrosine kinase therapy. We use these cases to elucidate an under-recognized treatment-related complication and to discuss the highly complex medical and surgical decision-making process when treating advanced GISTs. We aim to convey the rationale supporting a more aggressive surgical approach, when appropriate, as well as to emphasize the importance of strong medical and surgical collaboration for these cases.
No takes yet. Share an insight, caveat, or question.
Hartlein et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: